Mucopolysaccharidosis Pipeline Summary

DelveInsight’s, “Mucopolysaccharidosis - Pipeline Insight, 2026” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Mucopolysaccharidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mucopolysaccharidosis: Understanding

Mucopolysaccharidosis: Overview

Mucopolysaccharidosis (MPS) is a group of rare inherited lysosomal storage disorders characterized by defective degradation of glycosaminoglycans (GAGs) due to deficiencies in specific lysosomal enzymes. The resulting accumulation of undegraded GAGs within lysosomes affects multiple organs, including the skeletal, ocular, cardiovascular, respiratory, gastrointestinal, and central nervous systems. MPS comprises several subtypes with variable severity, ranging from relatively mild disease with near-normal life expectancy to rapidly progressive forms associated with severe multisystem involvement and early mortality. Ocular manifestations, particularly corneal clouding, glaucoma, retinopathy, and optic nerve involvement, can contribute substantially to visual impairment.

MPS is caused by pathogenic genetic variants resulting in deficiency or dysfunction of enzymes required for lysosomal GAG degradation. The specific enzyme deficiency determines the MPS subtype and the type of GAG that accumulates. For example, MPS I results from ?-L-iduronidase deficiency, MPS II from iduronate-2-sulfatase deficiency, MPS III from deficiencies in enzymes involved in heparan sulfate degradation, and MPS IV from defects affecting keratan sulfate degradation. Most MPS types are inherited in an autosomal recessive manner, whereas MPS II (Hunter syndrome) is X-linked.

The underlying enzyme deficiency prevents the normal lysosomal breakdown of GAGs, resulting in their progressive accumulation within cells and tissues. This lysosomal storage disrupts cellular function and produces widespread tissue and organ damage. Accumulation of GAGs such as heparan sulfate, dermatan sulfate, keratan sulfate, and chondroitin sulfates contributes to skeletal abnormalities, hepatosplenomegaly, cardiovascular and respiratory dysfunction, neurological impairment, and ocular abnormalities. In the eye, GAG deposition can produce diffuse corneal clouding, while associated retinal and optic nerve involvement may further impair vision.

Diagnosis of MPS is based on the combination of clinical manifestations, biochemical testing, enzyme activity assessment, and molecular genetic analysis. Clinical suspicion may arise from characteristic findings such as coarse facial features, short stature, skeletal abnormalities, hepatosplenomegaly, joint contractures, respiratory disease, developmental or cognitive impairment, and corneal clouding. Measurement of urinary or blood GAGs can support the diagnosis, while demonstrating deficient activity of the relevant lysosomal enzyme helps establish the specific MPS subtype. Molecular genetic testing can subsequently identify pathogenic variants and confirm the diagnosis.

Treatment of MPS is multidisciplinary and aims to reduce disease progression, manage organ-specific complications, and improve quality of life. Enzyme replacement therapy (ERT) is available for several MPS subtypes and works by supplying the deficient enzyme to reduce lysosomal GAG storage, particularly in visceral organs; however, its effect on the central nervous system and ocular tissues is limited by biological barriers. Hematopoietic stem cell transplantation (HSCT) is an important treatment option, particularly when performed early in selected patients with MPS I, although it does not reliably prevent ocular disease. Supportive treatment and surgery are used to manage individual complications, while severe corneal clouding may require corneal transplantation. Emerging approaches such as targeted gene therapy and substrate-reduction therapy are being investigated but, according to the reviewed article, remain experimental for ocular disease.

"Mucopolysaccharidosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucopolysaccharidosis pipeline landscape is provided which includes the disease overview and Mucopolysaccharidosis treatment guidelines. The assessment part of the report embraces, in depth Mucopolysaccharidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucopolysaccharidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Mucopolysaccharidosis R&D. The therapies under development are focused on novel approaches to treat/improve Mucopolysaccharidosis.

Mucopolysaccharidosis Emerging Drugs Chapters

This segment of the Mucopolysaccharidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mucopolysaccharidosis Emerging Drugs

• OTL-203: Orchard Therapeutics

OTL-203 is an investigational hematopoietic stem cell gene therapy which uses a modified virus to insert a functional copy of the human IDUA gene into a patient’s cells. OTL-203 was originated by, and initially developed in partnership with, the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. OTL-203 has received Rare Pediatric Disease (RPD) and Fast Track designations from the U.S. FDA, as well as priority medicines (PRIME) status from the EMA. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Mucopolysaccharidosis type I (MPS-I)’s most severe subtype, called Hurler syndrome (MPS-IH).

• Zafinofusp alfa (DNL126): Denali Therapeutics

DNL126 is an investigational enzyme replacement therapy which consists of recombinant N-sulfoglucosamine sulfohydrolase (SGSH) engineered with Denali’s Enzyme TransportVehicle™ (ETV) technology to facilitate transport across the blood–brain barrier. By delivering SGSH to the central nervous system and peripheral tissues, DNL126 is designed to restore lysosomal degradation of heparan sulfate and reduce its pathological accumulation, with the potential to address the neurological and systemic manifestations of MPS IIIA. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Mucopolysaccharidosis III.

• JR-446: JCR Pharmaceuticals

JR-446 is an investigational enzyme replacement therapy which applies JCR's proprietary J-Brain Cargo® technology, which is designed to deliver therapeutic enzymes across the blood–brain barrier via transferrin receptor-mediated transport. JR-446 consists of a recombinant ?-N-acetylglucosaminidase (NAGLU) enzyme fused with J-Brain Cargo®, enabling delivery of the enzyme to the central nervous system. By supplementing the deficient NAGLU enzyme, JR-446 is intended to reduce the accumulation of heparan sulfate, the substrate that accumulates in patients with MPS IIIB due to NAGLU deficiency. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Mucopolysaccharidosis III also known as Sanfilippo Syndrome.

• GC1130A: GC Biopharma Corp./ Novel Pharma

GC1130A is an investigational intracerebroventricular (ICV) enzyme replacement therapy (ERT) being developed by GC Biopharma Corp. in collaboration with Novel Pharma for the treatment of Sanfilippo syndrome type A (MPS IIIA). The therapy consists of recombinant human heparan N-sulfatase (rhHNS) and is administered directly into the cerebral ventricles via an intracerebroventricular access device to bypass the blood–brain barrier. GC1130A is intended to replace the deficient heparan N-sulfatase enzyme in patients with MPS IIIA, thereby reducing the accumulation of heparan sulfate, which causes central nervous system damage and progressive neurodegeneration. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Sanfilippo Syndrome.

Further product details are provided in the report……..

Mucopolysaccharidosis: Therapeutic Assessment

This segment of the report provides insights about the different Mucopolysaccharidosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Mucopolysaccharidosis

There are approx. 35+ key companies which are developing the therapies Mucopolysaccharidosis. The companies which have their Mucopolysaccharidosis drug candidates in the most advanced stage, i.e. Phase III include, Orchard Therapeutics and others.

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Mucopolysaccharidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucopolysaccharidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucopolysaccharidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucopolysaccharidosis drugs.

Mucopolysaccharidosis Report Insights

• Mucopolysaccharidosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mucopolysaccharidosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mucopolysaccharidosis drugs?
• How many Mucopolysaccharidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucopolysaccharidosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mucopolysaccharidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mucopolysaccharidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• JCR Pharmaceuticals
• GC Biopharma Inc.
• Novel Pharma
• Denali Therapeutics
• Ultragenyx Pharmaceutical Inc.
• Orchard Therapeutics
• Sangrail Biologics
• Regenxbio Inc.
• ProQR Therapeutics

Key Products

• JR-446
• GC1130A
• DNL126
• UX111
• OTL-201
• SNG-101
• RGX-121 (clemidsogene lanparvovec)
• OTL-203
• AX-0422
• JR-441